Paindrainer AB is selected to the prestigious Prevent2Care Program upheld by Ramsay Santé Foundation and Pfizer Innovation France
MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB, is pleased to announce its selection for the prestigious Prevent2Care Lab Program. This program provides invaluable access to the extensive business expertise of the Ramsay Santé Group, a European leader in the private hospitalization, embodying their commitment to innovation.
Initiated by the Ramsay Santé Foundation and backed by Pfizer Innovation France, the Prevent2Care Lab is dedicated to supporting innovative solutions in the field of preventive healthcare. In collaboration with the regional structures – Capio in Sweden and Denmark, and Volvat in Norway – the program aims to significantly enhance the impact and growth of preventive healthcare startups. Paindrainer AB is joining the Nordic cohort of Prevent2Care.
The comprehensive 9-month program combines collective and individualized support, featuring exclusive guidance from Ramsay Santé Group experts, fundraising support, and access to health expertise and partner networks.
We are honored to have been selected for the Prevent2Care Lab Program. This opportunity comes at a pivotal moment for Paindrainer AB as we continue to pioneer cutting-edge innovations in chronic pain management. The support from Ramsay Santé and Pfizer, with their extensive expertise and resources, will play a crucial role in accelerating our growth and expanding our potential to impact the chronic pain arena, including head and neck pain, lower back pain, neuropathic pain, and migraines. This will serve as a significant milestone in advancing our presence across Europe. Our participation in this program underscores our dedication to advancing digital healthcare and enhancing quality of life through preventive measures," says Erik Frick, CEO of Paindrainer AB.
The Paindrainer® mobile application is the first evidence-based digital tool demonstrating improved quality of life for individuals living with chronic pain. The product is FDA registered as a Medical Device Class I. The solution is powered by leveraging advanced neural networks and is fully adaptive to each individual patient, featuring the unique proprietary and patented 360o patient-centric approach. This approach provides guidance on achieving a personalized activity balance to reach an optimal functional level and alleviate pain.
For more information, please contact:
Erik Frick
CEO Paindrainer AB
erik.frick@paindrainer.com
+46 736 61 21 23
Paindrainer AB is a company developing digital platforms and applications contributing to health and well-being. Paindrainer was founded in 2018 by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement, and Göran Barkfors. The idea was born when Maria, after participating in several pain rehabilitation programs, realized that pain is affected by many more factors than the human brain can comprehend.
Paindrainer® is the first evidence-based AI powered digital tool demonstrating improved quality of life in individuals living with chronic pain. The digital tool coaches the users in managing their pain and provides guidance on how to reach a personalized activity balance to reach an optimal functional level and alleviate pain. The solution is powered by leveraging advanced algorithms and is fully adaptive to each user, a feature called 360o patient-centricity©.
Paindrainer® (Paindrainer PD1) is an FDA registered Medical Device Class 1 (510k exemption), MDR compliant and CE certified.